Panobacumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Pseudomonas aeruginosa serotype IATS O11 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C38714H60189N10637O12187S322 |
Molar mass | 879959.96 g·mol−1 |
(what is this?) |
Panobacumab (proposed INN) is a monoclonal antibody designed as an antibacterial against Pseudomonas aeruginosa.[1]
It is a fully human pentameric IgM antibody with a mouse J chain.[1]
Development[]
Panobacumab is being developed by . As of November 15th it is in phase 2 clinical trials. The originator was .[2]
The mechanism of action is as a lipopolysaccharide inhibitor.[2]
References[]
- ^ a b International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
- ^ a b "Panobacumab - Aridis Pharmaceuticals - AdisInsight". Retrieved 15 November 2019.
Categories:
- Drugs not assigned an ATC code
- Monoclonal antibodies
- Experimental drugs
- Antiinfective agent stubs
- Monoclonal antibody stubs